Navigation Links
BioMarin to Present at the Barclays Capital Global Healthcare Conference
Date:3/17/2010

NOVATO, Calif., March 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare Conference in Miami on Wednesday, March 24, 2010 at 9:30 a.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU; GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA and BMN 195, which is currently in Phase I clinical development for the treatment of Duchenne Muscular Dystrophy. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

    
    
    Contacts:
    
    Investors                          Media
    Eugenia Shen                       Susan Berg
    BioMarin Pharmaceutical Inc.       BioMarin Pharmaceutical Inc.
    (415) 506-6570                     (415) 506-6594

SOURCE BioMarin Pharmaceutical Inc.

Back to top

RELATED LINKS
http://www.bmrn.com

'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarins Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
2. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
3. BioMarin to Present at the Morgan Stanley Healthcare Conference
4. BioMarin to Present at the Baird Healthcare Conference
5. BioMarin to Present at the Jefferies Healthcare Conference
6. BioMarin to Present at the Goldman Sachs Healthcare Conference
7. BioMarin to Present at the Deutsche Bank Health Care Conference
8. BioMarin to Present at the Baird Growth Stock Conference
9. BioMarin Announces First Quarter 2009 Financial Results
10. BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
11. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... PA (PRWEB) , ... May 22, 2017 , ... ... announced today that it is exhibiting in booth B2 at the Association for ... Pittsburgh, May 22-25. , In addition to demonstrating its Cancer Diagnostic Cockpit ...
(Date:5/19/2017)... ... 19, 2017 , ... In response to the strong base of evidence supporting ... announces the release of their Gait Trainer 3 with an Integrated Music Therapy option. ... to aid in rehabilitating individuals with cerebral palsy, traumatic brain injury, stroke and Parkinson’s ...
(Date:5/18/2017)... ... May 18, 2017 , ... Lajollacooks4u has added another ... a two-hour team-building package designed for groups of 10-30 people. Guests can ... include items, such as Blackened Shrimp with Edamame Salad, Pizza Rolls with Pepperoni ...
(Date:5/18/2017)... (PRWEB) , ... May 17, ... ... CRO standards with psychonneuroendocrine stress expertise, and further enhances its scientific power ... researcher, Douglas A. Granger, Ph.D., has agreed to join the scientific advisory ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced Design ... will feature emerging and evolving technology through its ... Summits will run alongside the expo portion of the ... panels and demonstrations focused on trending topics within 3D ... design and manufacturing event will take place June 13-15, 2017 ...
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
Breaking Biology News(10 mins):